Introduction
============

Livestock animals are subjected to a huge sort of stress factors, such as environmental conditions, animal management or diets that may disrupt the intestinal ecosystem and increase the risk of pathogenic infections. In the swine industry, transition from the liquid to a solid diet during weaning and post-weaning are critic processes due to an important decrease of feed intake, impairing animal performance, immune function, microbiota and therefore, gut homeostasis.[@R1] Concerning the immune system, these performance stages lead to the end of transference of passive maternal immunity from the sows to the piglets which still have an immature or developing immune system.[@R2] This means that piglets become highly susceptible to intestinal pathogens such as enterotoxigenic *E.coli* (ETEC) or *Salmonella enterica* ser. Typhimurium (hereafter *Salmonella*).

Antibiotic growth promoters (AGPs) have been extensively used as dietary additives to minimize the risk of infections, especially during the critical periods of animal production, like weaning. However, after European ban of AGPs (EC 1831/2003) several studies proposed the use of probiotics and prebiotics as natural alternatives to AGPs.[@R1] In that sense, the health benefits of probiotics and prebiotics have been widely accepted as gut microbiota stabilizers because they are believed to avoid pathogenic colonization and therefore improving animal welfare.[@R3]^,^[@R4]

Our group recently published in vitro results that demonstrated the potential of probiotic *Saccharomyces cerevisiae* var Boulardii and prebiotic β-galactomannan (βGM) to prevent intestinal infections by *E.coli*[@R5] and *Salmonella*[@R6] in pigs. Here, we aimed to extend the knowledge about the prebiotic role of βGM against *Salmonella* challenge according to its polysaccharide structure.

Methods
=======

Intestinal epithelial cell culture (IECs)
-----------------------------------------

The porcine small intestine epithelial cell line IPI-2I (ECACC 93100622) was established from the ileum of an adult boar (SLAd/d haplotype).[@R7] IPI-2I cells were maintained in DMEM glutamax (Invitrogen, Spain) supplemented with 10% FCS (Invitrogen), insulin 10 µg/ml (Sigma--Aldrich, Saint-Quentin, France). In all experiments, cells were cultured in 6-well plates (Nunc, Labclinics, Spain) to confluence. Before the addition of pre/probiotics and/or infection, cells were washed three times and the cell culture was replaced with DMEM media supplemented with insulin 10 µg/ml (Sigma--Aldrich). Cells were used between passages 30 and 70 and periodically tested to avoid Mycoplasma contamination (MycoAlert® Mycoplasma Detection Kit, Lonza).

Experimental treatments and prebiotic preparation
-------------------------------------------------

To assess the functionality of mannans according to their structure we compared the prebiotic βGM (Salmosan©, patent WO2009/144070 A2, licensed to Industrial Técnica Pecuaria, ITPSA, Barcelona, Spain) to another mannanoligosaccharide purified from *Saccharomyces cerevisiae* (Mannan SC, Sigma) and to D-Mannose monosaccharide (Sigma-Aldrich) in relation to a negative control (medium).

Prebiotic βGM, Mannan SC and D-Mannose were diluted in DMEM glutamax (1 mg/ml), vortexed and incubated 30 min at 37°C. Immediately before the *Salmonella* infection, βGM, Mannan SC and D-Mannose were respectively added to each well at 10µg/ml.

Host cell-pathogen assay
------------------------

Pathogenic *Salmonella enterica* serovar Typhimurium (*Salmonella*) with antigenic formulae (4,12:i:1,2), resistant to ampicillin, chloramphenicol, streptomycin, sulfonamide and tetracycline was provided by Dr. Ignacio Badiola from Centre Recerca en Sanitat Animal (CReSA, IRTA-UAB, Bellaterra, Spain). Aliquots of Salmonella were provided in bacterial cryo-preservers (Technical Service Consultants, Ferrer International, Spain) and stored at -80°C until use. Before infection IEC cells, a single Salmonella cryo-preserver was added to 20 ml of Luria-Bertani media (LB) and cultured for 3--4h at 37°C with 180 rpm rotational agitation (Multitron HT, Infors). For infection, *Salmonella* was used during the exponential growth phase as determined by absorbance at 600 nm. *Salmonella* was used at MOI = 4 as previously described.[@R6] After 3 h of host cell-pathogen assay performed as described before, 75µg/ml of Gentamycin (Sigma-Aldrich) were added to each well to avoid bacterial overgrowth. After 24 h, supernatants were sampled and stored at -80°C until analysis.

Determination of cytokine production
------------------------------------

Cytokine protein determination in the culture supernatant was performed by enzyme-linked immunosorbent assays (ELISAs). Swine IL-6 and CXCL8 DuoSet ELISA kits (R&D Systems, Vitro SP) were used according to manufacturer's recommendations.

Statistical analysis
--------------------

All statistical analyses were performed using GLM procedure (PROC GLM) by SAS Software version 9.1.3 (SAS institute). Means for protein secretion were considered in a 2\*3 factorial design (two infection levels \* 3 experimental treatments) with Duncan's post-test for group analysis. The P value ≤ 0.05 was considered to be significant. Superscript letters are used to designate statistical significance: Bars with different superscript letters are significantly different (p \< 0.05) and bars with same superscript letters indicate no statistical difference (n.s).

Results and Discussion
======================

Many intestinal pathogenic strains of *Salmonella* and *E.coli* share type I fimbriae, although from different evolutionary origin, which have high affinity for mannose residues of glycoproteins present on cell surface of the host.[@R4]^,^[@R8]^,^[@R9] The recognition of these residues leads to bacterial adherence to enterocyte surface and intestinal colonization by the pathogen. Our recent articles showed how probiotic strain of *Saccaromyces cerevisiae* var Boulardii (*Scb*) and a recently developed prebiotic β-galactomannan (βGM), derived from fruit seed of the *Ceratonia silliqua* tree, inhibit in vitro adhesion of *Salmonella*[@R6] and ETEC[@R5] to pig intestinal cell line IPI-2I. Indeed, both products decreased the overall proinflammatory profile induced by ETEC or *Salmonella*, with the least expenditure of resources for innate immune response to deal with each pathogen.

Mannan derived products, such as *Scb* and βGM, are widely accepted to prevent *Salmonella* colonization by binding to the adhesin Fim H of the type I fimbriae. The interaction of probiotic *Scb* and prebiotic βGM was already confirmed in our previous work.[@R6] However, enterotoxigenic *E.coli* K88, which is one on the most important causes of neonatal and post-weaning diarrhea (PWD) in piglets, bears type IV fimbriae or pilli.[@R10] The latter has been described as mannose resistant to erythrocyte agglutination test in the presence of D-Mannose (5%).[@R11] Nevertheless, the K88 adhesins (ab, ac and ad) bind to β-galactose residues of receptors of syalic glycoprotein and to neutral glycosphingolipids expressed on the surface of the intestinal mucosa.[@R12] The presence of β-galactose in *Scb* and βGM may mimic host receptor for K88 adhesin[@R4] and therefore inhibit ETEC attachement to cell surface.

In addition to the residue composition, prebiotic functionality is determined by the size and molecular structure of the saccharides.[@R13] Here, we evaluated functionality of βGM according to their polysaccharide structure. We compared βGM to monosaccharide D-mannose and to another mannan oligosaccharide purified from *Saccharomyces cerevisiae* yeast (Mannan SC) at a final concentration of 10 µg/ml. We observed that in vitro challenge with *Salmonella* induces the secretion of proinflammatory cytokine IL6 (4-fold increase: 224 vs. 897 pg/ml ; [Figure 1A](#F1){ref-type="fig"}) and chemokine CXCL8 (2-fold increase: 2645 vs. 5192 pg/ml; [Figure 1B](#F1){ref-type="fig"}) compared with control without infection. Both, βGM and Mannan SC showed a 40% reduction of *Salmonella*-induced secretion of IL6 (897 vs. 563 and 585 pg/ml, [Figure 1A](#F1){ref-type="fig"}). Concerning CXCL8, βGM reduce chemokine secretion by 30% (5192 vs 3697 pg/ml; [Figure 1B](#F1){ref-type="fig"}). However, Mannan SC shows a trend to reduce CXCL8 secretion induced by Salmonella ([Fig. 1B](#F1){ref-type="fig"}). Interestingly, the secretion of proinflammatory IL6 and CXCL8 in IECs treated with monosaccharide D-mannose was similar to the control of infection ([Fig. 1A and B](#F1){ref-type="fig"}). Present data confirms early results shown by Oyofo et al.[@R14]^,^[@R15] and Vilà et al.[@R16] who showed higher efficiency of oligomeric mannoses compared with monomeric D-mannose to inhibit in vivo Salmonella infection in other productive species like chickens. In pigs, the addition of a commercial source of mannanoligosaccharides in the diet increased weight gain during the starter period, improved feed efficiency in vivo together with a reduction of enterobacteria counts in the jejunum (see ref. [@R17]). Indeed, mannanoligosaccharide additives have been shown to modify the composition of the gastrointestinal microbiota, resulting in increased populations of *Bacteroidetes spp* and *Lactobacillus* spp after *Salmonella* infection in vivo, leading to a greater compensatory weight gain of pigs (see ref. [@R18])

![**Figure 1.** Effect of oligosaccharide structure on IL6 and CXCL8 secretion induced by *Salmonella*. Cytokine IL6 (**A**) and chemokine CXCL8 (**B**) concentration in supernatants from IPI-2I cells (1 × 10^6^ cells/well) co-cultured for 24 h with *Salmonella* (MOI = 4) is decreased by βGM and Mannan SC (10 µg/ml). Bars with different superscript letters have statistically significant difference (p \< 0.05). Data are representative of 3 independent experiments.](gmic-4-72-g1){#F1}

In this regard, our previous in vitro works showed that *Scb* has a higher anti-inflammatory role in ETEC infections.[@R5] In contrast, βGM is a potent prophylactic agent against *Salmonella* infections.[@R6] Therefore, the preference of the use of each probiotic or prebiotic additive as a dietary alternative to AGPs, should be determined, if possible, according to the specific conditions of each farm. This means the prevalence of ETEC or *Salmonella* of each productive facility or region. In that sense, considering that ETEC infections often occur during weaning,[@R19] while *Salmonella* usually colonizes post-weaning and finishing growing pigs,[@R20] to enrich diets with *Scb* at early stages to prevent ETEC infections and with βGM to reduce *Salmonella* prevalence at final growing stages should be considered. In addition, we hypothesize that the prebiotic βGM may enhance probiotic *Scb* survival and colonization of the intestinal tract improving host health.[@R21] Future studies should determine the suitability to combine βGM and *Scb* to become a symbiotic additive to prevent intestinal infections .

Nowadays in EU, products such as Mannan SC and βGM are not authorized as zootechnical feed additives under the commission regulation (EC) 1831/2003.[@R22] In the future, both products could be authorized following concepts described in the opinion of EFSA (see ref. [@R23]) concerning potential new categories of zootechnical feed additives. In this case it would be additives which improve product quality as "Microbial contamination controllers ". However, today it is also possible to introduce them in the European feed legislation according to the regulation (EC) 767/2009[@R24] where there is a description of how ingredients can be used for particular purposes.

In conclusion, we demonstrated that oligosaccharide structure is crucial for mannans to develop their prebiotic role to inhibit pathogenic adhesion and therefore to reduce proinflamatory immune response induced by the pathogen.
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